Drug Type Small molecule drug |
Synonyms BPG-0812 |
Target |
Action inhibitors |
Mechanism UBE2K inhibitors(ubiquitin conjugating enzyme E2 K inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Huntington Disease-Like Syndrome | Preclinical | United States | 02 Oct 2024 |





